obesity

Page 3 of 12

Companies are more willing to consider covering weight-loss drugs
Health

Companies are more willing to consider covering weight-loss drugs

By
October 10, 2024
Ozempic goes from threat to opportunity for packaged-food makers
Health

Ozempic goes from threat to opportunity for packaged-food makers

By Deena Shanker and Bloomberg
October 2, 2024
As of March 2024, the Centers for Disease Control and Prevention no longer advises a five-day isolation period when you test positive for COVID-19, but recommends taking other precautions once your symptoms subside.
Health

Got COVID? Here are the new 2024 isolation guidelines

By
September 27, 2024
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
Finance

Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’

By Sara Sjolin, Sanne Wass, Oliver Crook and Bloomberg
September 23, 2024
Asian female doctor is working in laboratory wearing PPE. She holds an instrument and a petri dish.
Finance

Obesity drugmaker BioAge targets $158 million in IPO

By David Morris and Bloomberg
September 18, 2024
An Ozempic (semaglutide) injection pen is seen on a kitchen table.
Health

How Denmark got homegrown giant Novo Nordisk to lower Ozempic prices

By Arthur Allen and KFF Health News
August 7, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S's obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty Images
Retail

Europe’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow

By
August 7, 2024
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary

I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad

By
July 30, 2024
Thomas Schinecker, CEO of Roche Holding.
Retail

An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value

By Naomi Kresge, Lisa Pham and Bloomberg
July 23, 2024
Obesity medicine physician Dr. Nisha Patel breaks down five weight loss myths that “need to die” with Fortune.
Health

The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor

By
July 18, 2024
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
Health

Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs

By
June 28, 2024
EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
Health

EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics

By Naomi Kresge and Bloomberg
June 26, 2024
‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults
Health

‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults

By Jonel Aleccia and The Associated Press
May 22, 2024
Dr. Razia Hashmi, vice president of clinical affairs, Blue Cross Blue Shield Association, speaks during Fortune’s Brainstorm Health conference in Dana Point, Calif., on Tuesday, May 21, 2024.
Health

GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study

By
May 22, 2024
People living with obesity reap the greatest health benefits from being physically active in the evening, according to a new Australian study.
Life

This is the best time of day to exercise for people living with obesity, new study shows

By
May 18, 2024

Most Popular